EP0651999A1 - Hemmung uteriner Fibrose - Google Patents
Hemmung uteriner Fibrose Download PDFInfo
- Publication number
- EP0651999A1 EP0651999A1 EP94307521A EP94307521A EP0651999A1 EP 0651999 A1 EP0651999 A1 EP 0651999A1 EP 94307521 A EP94307521 A EP 94307521A EP 94307521 A EP94307521 A EP 94307521A EP 0651999 A1 EP0651999 A1 EP 0651999A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- compound
- uterine fibrosis
- starch
- formula
- methods
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 0 Oc(cc1)ccc1-c([s]c1c2)c(C(c3ccc(*N4CCCCC4)cc3)=O)c1ccc2O Chemical compound Oc(cc1)ccc1-c([s]c1c2)c(C(c3ccc(*N4CCCCC4)cc3)=O)c1ccc2O 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
Definitions
- Uterine fibrosis is an old and ever present clinical problem which goes under a variety of names, including uterine hypertrophy, uterine lieomyomata, myometrial hypertrophy, fibrosis uteri, and fibrotic metritis.
- uterine fibrosis is a condition where there is an inappropriate deposition of fibroid tissue on the wall of the uterus.
- This condition is a cause of dysmenorrhea and infertility in women.
- the exact cause of this condition is poorly understood but evidence suggests that it is an inappropriate response of fibroid tissue to estrogen.
- Such a condition has been produced in rabbits by daily administrations of estrogen for 3 months.
- guinea pigs the condition has been produced by daily administration of estrogen for four months.
- estrogen causes similar hypertrophy.
- uterine fibrosis involves surgical procedures both costly and sometimes a source of complications such as the formation of abdominal adhesions and infections.
- initial surgery is only a temporary treatment and the fibroids regrow.
- a hysterectomy is performed which effectively ends the fibroids but also the reproductive life of the patient.
- gonadotropin releasing hormone antagonists may be administered, yet their use is tempered by the fact they can lead to osteoporosis.
- This invention provides methods for inhibiting uterine fibrosis, comprising administering to a human or other mammal in need of treatment an effective amount of a compound of formula I Wherein R1 and R3 are independently hydrogen, -CH3, or wherein Ar is optionally substituted phenyl; R2 is selected from the group consisting of pyrrolidino and piperidino; and pharmaceutically acceptable salts and solvates thereof.
- the current invention concerns the discovery that a select group of 2-phenyl-3-aroylbenzothiophenes (benzothiophenes), those of formula I, are useful for inhibiting uterine fibrosis.
- the methods of treatment provided by this invention are practiced by administering to a human in need of inhibition of uterine fibrosis, a dose of a compound of formula I or a pharmaceutically acceptable salt or solvate thereof, that is effective to inhibit uterine fibrosis.
- the term inhibit is defined to include its generally accepted meaning which includes prophylactically treating a human subject to incurring uterine fibrosis, and holding in check and/or treating existing uterine fibrosis.
- the present method includes both medical therapeutic and/or prophylactic treatment, as appropriate.
- the compound is formulated with common excipients, diluents or carriers, and compressed into tablets, or formulated as elixirs or solutions for convenient oral administration, or administered by the intramuscular or intravenous routes.
- the compounds can be administered transdermally, and may be formulated as sustained release dosage forms and the like.
- the compounds used in the methods of the current invention can be made according to established procedures, such as those detailed in U.S. Patent Nos. 4,133,814, 4,418,068, and 4,380,635 all of which are incorporated by reference herein.
- the process starts with a benzo[b]thiophene having a 6-hydroxyl group and a 2-(4-hydroxyphenyl) group.
- the starting compound is protected, alkylated, and deprotected to form the formula I compounds. Examples of the preparation of such compounds are provided in the U.S. patents discussed above.
- Substituted phenyl includes phenyl substituted once or twice with C1-C6 alkyl, C1-C4 alkoxy, hydroxy, nitro, chloro, fluoro, or tri(chloro or fluoro)methyl.
- the compounds used in the methods of this invention form pharmaceutically acceptable acid and base addition salts with a wide variety of organic and inorganic acids and bases and include the physiologically acceptable salts which are often used in pharmaceutical chemistry. Such salts are also part of this invention.
- Typical inorganic acids used to form such salts include hydrochloric, hydrobromic, hydroiodic, nitric, sulfuric, phosphoric, hypophosphoric and the like.
- Such pharmaceutically acceptable salts thus include acetate, phenylacetate, trifluoroacetate, acrylate, ascorbate, benzoate, chlorobenzoate, dinitrobenzoate, hydroxybenzoate, methoxybenzoate, methylbenzoate, o-acetoxybenzoate, naphthalene-2-benzoate, bromide, isobutyrate, phenylbutyrate, ⁇ -hydroxybutyrate, butyne-1,4-dioate, hexyne-1,4-dioate, caprate, caprylate, chloride, cinnamate, citrate, formate, fumarate, glycollate, heptanoate, hippurate, lactate, malate, maleate, hydroxymaleate, malonate, mandelate, mesylate, nicotinate, isonicotinate, nitrate, oxalate, phthalate, teraphthalate, phosphate, monohydrogenphosphat
- the pharmaceutically acceptable acid addition salts are typically formed by reacting a compound of formula I with an equimolar or excess amount of acid.
- the reactants are generally combined in a mutual solvent such as diethyl ether or benzene.
- the salt normally precipitates out of solution within about one hour to 10 days and can be isolated by filtration or the solvent can be stripped off by conventional means.
- Bases commonly used for formation of salts include ammonium hydroxide and alkali and alkaline earth metal hydroxides and carbonates, as well as aliphatic and aromatic amines, aliphatic diamines and hydroxy alkylamines.
- Bases especially useful in the preparation of addition salts include ammonium hydroxide, potassium carbonate, sodium bicarbonate, calcium hydroxide, methylamine, diethylamine, ethylene diamine, cyclohexylamine and ethanolamine.
- the pharmaceutically acceptable salts generally have enhanced solubility characteristics compared to the compound from which they are derived, and thus are often more amenable to formulation as liquids or emulsions.
- compositions can be prepared by procedures known in the art.
- the compounds can be formulated with common excipients, diluents, or carriers, and formed into tablets, capsules, suspensions, powders, and the like.
- excipients, diluents, and carriers that are suitable for such formulations include the following: fillers and extenders such as starch, sugars, mannitol, and silicic derivatives; binding agents such as carboxymethyl cellulose and other cellulose derivatives, alginates, gelatin, and polyvinyl pyrrolidone; moisturizing agents such as glycerol; disintegrating agents such as agaragar, calcium carbonate, and sodium bicarbonate; agents for retarding dissolution such as paraffin; resorption accelerators such as quaternary ammonium compounds; surface active agents such as cetyl alcohol, glycerol monostearate; adsorptive carriers such as kaolin and bentonite; and lubricants such as talc, calcium and magnesium
- the compounds can also be formulated as elixirs or solutions for convenient oral administration or as solutions appropriate for parenteral administration, for instance by intramuscular, subcutaneous or intravenous routes. Additionally, the compounds are well suited to formulation as sustained release dosage forms and the like.
- the formulations can be so constituted that they release the active ingredient only or preferably in a particular part of the intestinal tract, possibly over a period of time.
- the coatings, envelopes, and protective matrices may be made, for example, from polymeric substances or waxes.
- the particular dosage of a compound of formula I required to inhibit uterine fibrosis, according to this invention will depend upon the severity of the condition, the route of administration, and related factors that will be decided by the attending physician. Generally, accepted and effective daily doses will be from about 0.1 to about 1000 mg/day, and more typically from about 50 to about 200 mg/day. Such dosages will be administered to a subject in need of treatment from once to about three times each day, or more often as needed to effectively inhibit uterine fibrosis.
- the invention also provides for a method of inhibiting uterine fibrosis by administering serially or concurrently a compound of the invention and a gonadotropin releasing hormone antangonist.
- Active ingredient means a compound of formula I.
- Hard gelatin capsules are prepared using the following: Ingredient Quantity (mg/capsule) Active ingredient 0.1 - 1000 Starch, NF 0 - 650 Starch flowable powder 0 - 650 Silicone fluid 350 centistokes 0 - 15 The ingredients are blended, passed through a No. 45 mesh U.S. sieve, and filled into hard gelatin capsules.
- a tablet formulation is prepared using the ingredients below:
- Ingredient Quantity (mg/tablet) Active ingredient 0.1 - 1000 Cellulose, microcrystalline 0 - 650 Silicon dioxide, fumed 0 - 650 Stearate acid 0 - 15 The components are blended and compressed to form tablets.
- tablets each containing 0.1 - 1000 mg of active ingredient are made up as follows:
- the active ingredient, starch, and cellulose are passed through a No. 45 mesh U.S. sieve and mixed thoroughly.
- the solution of polyvinylpyrrolidone is mixed with the resultant powders which are then passed through a No. 14 mesh U.S. sieve.
- the granules so produced are dried at 50°-60° C and passed through a No. 18 mesh U.S. sieve.
- the sodium carboxymethyl starch, magnesium stearate, and talc previously passed through a No. 60 U.S. sieve, are then added to the granules which, after mixing, are compressed on a tablet machine to yield tablets.
- the amount of compound administered is .1 to 1000 mg/day, and the period of administration is 3 months.
- the women are observed during the period of administration and up to 3 months after discontinuance of the compound for effects on uterine fibrosis.
- Tissue from human uterine fibroid tumors is harvested, and maintained in vitro as primary nontransformed cultures. Surgical specimens are pushed through a sterile mesh or sieve or alternately teased apart from surrounding tissue to produce a single cell suspension. Cells are maintained in media containing 10% serum and antibiotics. Rates of growth in the presence and absence of estrogen are determined. Cells are assayed for their ability to produce complement component C3 and their response to growth factors and growth hormone. In vitro cultures are assessed for their proliferative response following treatment with progestins, GnRH, a compound of the invention and vehicle. Levels of steroid hormone receptors are assessed weekly to determine whether important cell characteristics are maintained in vitro. Tissue from 5-25 patients are utilized.
- Activity in at least one of the above tests indicates the compounds of the invention are of potential in the treatment of uterine fibrosis.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/138,642 US5457116A (en) | 1993-10-15 | 1993-10-15 | Methods of inhibiting uterine fibrosis |
US138642 | 1999-06-10 |
Publications (2)
Publication Number | Publication Date |
---|---|
EP0651999A1 true EP0651999A1 (de) | 1995-05-10 |
EP0651999B1 EP0651999B1 (de) | 2002-04-24 |
Family
ID=22482959
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP94307521A Expired - Lifetime EP0651999B1 (de) | 1993-10-15 | 1994-10-13 | Hemmung uteriner Fibrose |
Country Status (23)
Country | Link |
---|---|
US (1) | US5457116A (de) |
EP (1) | EP0651999B1 (de) |
JP (1) | JPH07188015A (de) |
KR (1) | KR950010892A (de) |
CN (1) | CN1058389C (de) |
AT (1) | ATE216582T1 (de) |
AU (1) | AU680042B2 (de) |
CA (1) | CA2118090A1 (de) |
CZ (1) | CZ287247B6 (de) |
DE (1) | DE69430465T2 (de) |
DK (1) | DK0651999T3 (de) |
ES (1) | ES2172525T3 (de) |
HU (1) | HUT71236A (de) |
IL (1) | IL111285A (de) |
NO (1) | NO943878L (de) |
NZ (1) | NZ264678A (de) |
PH (1) | PH31596A (de) |
PT (1) | PT651999E (de) |
RU (1) | RU2145851C1 (de) |
SG (1) | SG46324A1 (de) |
TW (1) | TW327601B (de) |
UA (1) | UA27883C2 (de) |
ZA (1) | ZA948031B (de) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6515009B1 (en) | 1991-09-27 | 2003-02-04 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
US5811447A (en) | 1993-01-28 | 1998-09-22 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
USRE39049E1 (en) | 1992-07-28 | 2006-03-28 | Eli Lilly And Company | Methods for inhibiting bone loss |
USRE38968E1 (en) | 1992-07-28 | 2006-02-07 | Eli Lilly And Company | Methods for inhibiting bone loss using 6-hydroxy-2-(4-hydroxyphenyl)-benzo[b]thien-3-yl-4-[2-(piperidin-1-yl) ethoxyphenylimethanone hydrochloride |
TW366342B (en) * | 1992-07-28 | 1999-08-11 | Lilly Co Eli | The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss |
US6251920B1 (en) | 1993-05-13 | 2001-06-26 | Neorx Corporation | Prevention and treatment of cardiovascular pathologies |
US6491938B2 (en) | 1993-05-13 | 2002-12-10 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
US5595722A (en) | 1993-01-28 | 1997-01-21 | Neorx Corporation | Method for identifying an agent which increases TGF-beta levels |
JPH08510451A (ja) | 1993-05-13 | 1996-11-05 | ネオルックス コーポレイション | 異常増殖性平滑筋細胞に関連した病因の予防及び治療 |
US5478847A (en) | 1994-03-02 | 1995-12-26 | Eli Lilly And Company | Methods of use for inhibiting bone loss and lowering serum cholesterol |
US5856340A (en) * | 1995-02-28 | 1999-01-05 | Eli Lilly And Company | Method of treating estrogen dependent cancers |
ATE377418T1 (de) | 1995-06-07 | 2007-11-15 | Poniard Pharmaceuticals Inc | Vorbeugung und behandlung von kardiovaskulären beschwerden mit tamoxifen-analogen |
US5670523A (en) * | 1996-01-29 | 1997-09-23 | Eli Lilly And Company | Methods of inhibiting musculoaponeurotic fibromatoses (desmoid tumors) |
DE19604231A1 (de) * | 1996-01-29 | 1997-07-31 | Schering Ag | Pharmazeutisches Kombinationspräparat und seine Verwendung zur Behandlung von gynäkologischen Störungen |
CZ235398A3 (cs) * | 1996-01-29 | 1999-02-17 | Eli Lilly And Company | Farmaceutický prostředek pro inhibici muskuloaponeurotických fibromatóz savců zvláště lidí |
IL120266A (en) | 1996-02-28 | 2005-05-17 | Pfizer | Use of estrogen antagonists and estrogen agonists in the preparation of medicaments for inhibiting pathological conditions |
TW442286B (en) * | 1996-02-28 | 2001-06-23 | Pfizer | New therapeutic uses of estrogen agonists |
US5827876A (en) * | 1996-04-09 | 1998-10-27 | American Home Products Corporation | Inhibition of bone loss by 3-(4-acrylamidobenzoyl) benzo b!-thiophenes |
WO1998046588A2 (en) | 1997-04-11 | 1998-10-22 | Neorx Corporation | Compounds and therapies for the prevention of vascular and non-vascular pathologies |
EP1401446B1 (de) * | 2001-05-22 | 2005-02-09 | Eli Lilly And Company | Tetrahydrochinolin-derivate zur behandlung von krankheiten ausgelöst durch zu hohem oder zu niedrigem oestrogenspiegel |
JP2004531562A (ja) * | 2001-05-22 | 2004-10-14 | イーライ・リリー・アンド・カンパニー | 2−置換1,2,3,4−テトラヒドロキノリンおよびその誘導体、組成物ならびに方法 |
US20060106010A1 (en) * | 2003-05-27 | 2006-05-18 | Black Larry J | Methods for inhibiting bone loss |
US20080221163A1 (en) * | 2005-01-18 | 2008-09-11 | Jeffrey Alan Dodge | Selective Estrogen Receptor Modulators |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4418068A (en) * | 1981-04-03 | 1983-11-29 | Eli Lilly And Company | Antiestrogenic and antiandrugenic benzothiophenes |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4133814A (en) * | 1975-10-28 | 1979-01-09 | Eli Lilly And Company | 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents |
US4380635A (en) * | 1981-04-03 | 1983-04-19 | Eli Lilly And Company | Synthesis of acylated benzothiophenes |
US5075321A (en) * | 1987-03-24 | 1991-12-24 | University Of Pennsylvania | Methods of treating diseases characterized by interactions of IgG-containing immune complexes with macrophage Fc receptors using antiestrogenic benzothiophenes |
DE4122484A1 (de) * | 1991-07-06 | 1993-01-07 | Teves Gmbh Alfred | Schaltungsanordnung zur erkennung von radsensordefekten |
JP3157882B2 (ja) * | 1991-11-15 | 2001-04-16 | 帝国臓器製薬株式会社 | 新規なベンゾチオフエン誘導体 |
US5461065A (en) * | 1993-10-15 | 1995-10-24 | Eli Lilly And Company | Methods for inhibiting endometriosis |
US5418252A (en) * | 1993-10-15 | 1995-05-23 | Eli Lilly And Company | Method for inhibiting cartilage degradation |
US5457113A (en) * | 1993-10-15 | 1995-10-10 | Eli Lilly And Company | Methods for inhibiting vascular smooth muscle cell proliferation and restinosis |
-
1993
- 1993-10-15 US US08/138,642 patent/US5457116A/en not_active Expired - Lifetime
-
1994
- 1994-10-12 UA UA94105916A patent/UA27883C2/uk unknown
- 1994-10-13 AT AT94307521T patent/ATE216582T1/de not_active IP Right Cessation
- 1994-10-13 TW TW083109468A patent/TW327601B/zh active
- 1994-10-13 DE DE69430465T patent/DE69430465T2/de not_active Expired - Fee Related
- 1994-10-13 PH PH49187A patent/PH31596A/en unknown
- 1994-10-13 IL IL11128594A patent/IL111285A/en not_active IP Right Cessation
- 1994-10-13 PT PT94307521T patent/PT651999E/pt unknown
- 1994-10-13 EP EP94307521A patent/EP0651999B1/de not_active Expired - Lifetime
- 1994-10-13 NO NO943878A patent/NO943878L/no not_active Application Discontinuation
- 1994-10-13 DK DK94307521T patent/DK0651999T3/da active
- 1994-10-13 HU HU9402960A patent/HUT71236A/hu unknown
- 1994-10-13 SG SG1996002922A patent/SG46324A1/en unknown
- 1994-10-13 ES ES94307521T patent/ES2172525T3/es not_active Expired - Lifetime
- 1994-10-13 CN CN94117126A patent/CN1058389C/zh not_active Expired - Fee Related
- 1994-10-13 RU RU94037235A patent/RU2145851C1/ru active
- 1994-10-13 CZ CZ19942538A patent/CZ287247B6/cs not_active IP Right Cessation
- 1994-10-13 KR KR1019940026163A patent/KR950010892A/ko not_active Application Discontinuation
- 1994-10-13 CA CA002118090A patent/CA2118090A1/en not_active Abandoned
- 1994-10-13 JP JP6247768A patent/JPH07188015A/ja not_active Ceased
- 1994-10-13 ZA ZA948031A patent/ZA948031B/xx unknown
- 1994-10-13 NZ NZ264678A patent/NZ264678A/en unknown
- 1994-10-14 AU AU75834/94A patent/AU680042B2/en not_active Ceased
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4418068A (en) * | 1981-04-03 | 1983-11-29 | Eli Lilly And Company | Antiestrogenic and antiandrugenic benzothiophenes |
Non-Patent Citations (4)
Title |
---|
"Lilly's raloxifene entering phase III for osteoporosis", THE PINK SHEET, vol. 55, no. 16, 19 April 1993 (1993-04-19) * |
DATABASE FILE 187, FDC REPORTS Dialog Information Services; * |
LJ. BLACK ET AL.: "Antagonism of estrogen action with a new benzothiophene derived antiestrogen", LIFE SCIENCES, vol. 32, no. 9, pages 1031 - 1036, XP025566860, DOI: doi:10.1016/0024-3205(83)90935-9 * |
LJ. BLACK ET AL.: "Raloxifene (ly139481) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovarectomized rats", J. CLIN. INVEST., vol. 93, no. 1, pages 63 - 69 * |
Also Published As
Publication number | Publication date |
---|---|
CN1107156A (zh) | 1995-08-23 |
CZ253894A3 (en) | 1995-05-17 |
US5457116A (en) | 1995-10-10 |
ATE216582T1 (de) | 2002-05-15 |
IL111285A (en) | 1998-12-27 |
HU9402960D0 (en) | 1995-02-28 |
AU7583494A (en) | 1995-05-04 |
PH31596A (en) | 1998-11-03 |
RU2145851C1 (ru) | 2000-02-27 |
AU680042B2 (en) | 1997-07-17 |
DE69430465D1 (de) | 2002-05-29 |
DE69430465T2 (de) | 2002-10-31 |
CN1058389C (zh) | 2000-11-15 |
ES2172525T3 (es) | 2002-10-01 |
UA27883C2 (uk) | 2000-10-16 |
CZ287247B6 (en) | 2000-10-11 |
JPH07188015A (ja) | 1995-07-25 |
PT651999E (pt) | 2002-08-30 |
CA2118090A1 (en) | 1995-04-16 |
ZA948031B (en) | 1996-04-15 |
NO943878L (no) | 1995-04-18 |
SG46324A1 (en) | 1998-02-20 |
RU94037235A (ru) | 1996-11-10 |
KR950010892A (ko) | 1995-05-15 |
NO943878D0 (no) | 1994-10-13 |
DK0651999T3 (da) | 2002-06-17 |
HUT71236A (en) | 1995-11-28 |
IL111285A0 (en) | 1994-12-29 |
NZ264678A (en) | 1997-07-27 |
EP0651999B1 (de) | 2002-04-24 |
TW327601B (en) | 1998-03-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0651999B1 (de) | Hemmung uteriner Fibrose | |
EP0652005B1 (de) | Methode zur Hemmung der Endometriose | |
EP0652001B1 (de) | Behandlung Peri-menopausaler Syndrome | |
US5552416A (en) | Methods of inhibiting dysfunctional uterine bleeding | |
EP0652000B1 (de) | Verwendung von 2-phenyl-3-aroylbenzothiophen Derivaten zur Herstellung eines Medikaments zur Hemmung der Angiogenese und angiogene Krankheiten | |
EP0659411B1 (de) | Methode zur Erhöhung des Libidos bei Frauen nach die Menopause | |
US5451589A (en) | Methods of inhibiting ovarian dysgenesis, delayed puberty, or sexual infantilism | |
EP0652002A1 (de) | Hemmung des Knorpelabbaus | |
US5593987A (en) | Methods of inhibiting breast disorders | |
US5451590A (en) | Methods of inhibiting sexual precocity | |
EP0769945B1 (de) | Verwendung von 2-phenyl-3-aroylbenzothiophenderivaten zur herstellung eines medikaments zur knochen- und bruchheilung | |
US5494929A (en) | Methods of inhibiting growth hormone effects | |
EP0722727A1 (de) | Benzofuran-Derivate zur Hemmung der uterinem Fibrose |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 19941022 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU NL PT SE |
|
RAX | Requested extension states of the european patent have changed |
Free format text: LT PAYMENT 941022;SI PAYMENT 941022 |
|
17Q | First examination report despatched |
Effective date: 19960411 |
|
GRAG | Despatch of communication of intention to grant |
Free format text: ORIGINAL CODE: EPIDOS AGRA |
|
RIC1 | Information provided on ipc code assigned before grant |
Free format text: 7A 61K 31/4453 A, 7A 61K 31/4025 B, 7A 61K 31/55 B, 7A 61K 31/381 B, 7A 61P 15/02 B |
|
GRAG | Despatch of communication of intention to grant |
Free format text: ORIGINAL CODE: EPIDOS AGRA |
|
GRAH | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOS IGRA |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: IF02 |
|
GRAH | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOS IGRA |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU NL PT SE |
|
AX | Request for extension of the european patent |
Free format text: LT PAYMENT 19941022;SI PAYMENT 19941022 |
|
REF | Corresponds to: |
Ref document number: 216582 Country of ref document: AT Date of ref document: 20020515 Kind code of ref document: T |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: NV Representative=s name: E. BLUM & CO. PATENTANWAELTE |
|
REF | Corresponds to: |
Ref document number: 69430465 Country of ref document: DE Date of ref document: 20020529 |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: DK Ref legal event code: T3 |
|
ET | Fr: translation filed | ||
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: SE Payment date: 20020808 Year of fee payment: 9 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: PT Payment date: 20020813 Year of fee payment: 9 |
|
REG | Reference to a national code |
Ref country code: PT Ref legal event code: SC4A Free format text: AVAILABILITY OF NATIONAL TRANSLATION Effective date: 20020529 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: CH Payment date: 20020904 Year of fee payment: 9 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 20020920 Year of fee payment: 9 |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 2172525 Country of ref document: ES Kind code of ref document: T3 |
|
REG | Reference to a national code |
Ref country code: GR Ref legal event code: EP Ref document number: 20020402426 Country of ref document: GR |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20021014 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DK Payment date: 20021014 Year of fee payment: 9 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: LU Payment date: 20021018 Year of fee payment: 9 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: BE Payment date: 20021023 Year of fee payment: 9 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: AT Payment date: 20021025 Year of fee payment: 9 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GR Payment date: 20021029 Year of fee payment: 9 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 20021030 Year of fee payment: 9 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20021031 Year of fee payment: 9 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: ES Payment date: 20021112 Year of fee payment: 9 |
|
LTIE | Lt: invalidation of european patent or patent extension |
Effective date: 20020424 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
26N | No opposition filed |
Effective date: 20030127 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: NL Payment date: 20030430 Year of fee payment: 9 |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: MM4A |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20031013 Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20031013 Ref country code: AT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20031013 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20031014 Ref country code: ES Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20031014 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20031031 Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20031031 Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20031031 |
|
BERE | Be: lapsed |
Owner name: *ELI LILLY AND CY Effective date: 20031031 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: PT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20040430 Ref country code: DK Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20040430 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NL Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20040501 Ref country code: DE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20040501 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20040504 |
|
EUG | Se: european patent has lapsed | ||
GBPC | Gb: european patent ceased through non-payment of renewal fee |
Effective date: 20031013 |
|
REG | Reference to a national code |
Ref country code: DK Ref legal event code: EBP |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20040630 |
|
NLV4 | Nl: lapsed or anulled due to non-payment of the annual fee |
Effective date: 20040501 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: ST Ref country code: PT Ref legal event code: MM4A Free format text: LAPSE DUE TO NON-PAYMENT OF FEES Effective date: 20040430 |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FD2A Effective date: 20031014 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES;WARNING: LAPSES OF ITALIAN PATENTS WITH EFFECTIVE DATE BEFORE 2007 MAY HAVE OCCURRED AT ANY TIME BEFORE 2007. THE CORRECT EFFECTIVE DATE MAY BE DIFFERENT FROM THE ONE RECORDED. Effective date: 20051013 |